Company intelligence / Profile preview

PDC Global

Epalinges, Vaud, Switzerland

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Lead asset RS-0139 is in phase 1 clinical trials for advanced solid tumors, demonstrating strong translation of preclinical to clinical results; other programs remain in preclinical development.

Therapeutic areas: Oncology
Modalities: Polymer-drug conjugateNanoparticleSmall moleculeAntibody
Industry: Biotech

Partnerships

Multinational pharmaceutical companies for co-development

Beyond the preview

Go deeper on PDC Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDC Global.

Explore the full profile